Female subjects who are lactating must discontinue nursing prior to the first dose of study drug and refrain from nursing throughout the treatment period and for  days following the last dose of study drug
Male participants of childbearing potential must agree to use an adequate method of contraception during the study treatment period and for at least  days after the last dose of study treatment and refrain from donating sperm during this period.
Male participants must agree to refrain from donating sperm, to abstain or use a condom during the treatment period, and at least  days after last dose of study drug
Male participants must not be considering fathering a child or donating sperm during the study or for at least  or  months (for monotherapy and combination therapy participants, respectively) after the last dose of study drug.
Male participants who are considering fathering a child or donating sperm during the study or for at least  or  months (for monotherapy and combination therapy participants, respectively) after the last dose of study drug.
Male subjects must be willing to use a recommended method of contraception throughout the study period, and to refrain from sperm donation throughout the study period.
If male, must agree to use contraception or practice abstinence as well as refrain from donating sperm for at least  days after the last dose of study treatment.
If male, must agree to use contraception and refrain from donating sperm during the treatment period and for ? days after last dose of study treatment.
Male participants must refrain from donating sperm starting from the first dose of study medication, throughout the study period, and for up to  days after the last dose of study medication
Are currently abstinent, and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period or for  days after study drug discontinuation.
Pregnancy and breast feeding are exclusion factors; enrolled patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, the duration of study participation and  days (female patients) or  days (male patients) after the end of the treatment; in addition male patients must refrain from sperm donation for  days after the final dose of investigational product; female patients must refrain from egg cell donation for  days after the final dose of investigational product; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
Breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for  days following the last dose of study drug
A male participant must agree to use a contraception during the treatment period and for at least  days after the last dose of study treatment and refrain from donating sperm during this period\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant
Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until  days after the last dose of study drug administration until  days after the last dose of study drug.
Non-sterile male subjects must use contraceptive methods with partner(s) prior to beginning study drug administration and continuing up to  days after the last dose of study drug; male subjects must agree to refrain from sperm donation from initial study drug administration until  days after the last dose of study drug
Participants who are males and who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) and up to  months post last dose of study drug(s); in addition, male participants must be willing to refrain from sperm donation during this time
Male participants must agree to use approved contraception during the treatment period and for at least  days after the last dose of study treatment and refrain from donating sperm during this period
Subjects must be willing to refrain from sunbathing for the duration of the study.
Male Participants who are sexually active, must agree, from Study Day  through at least  days after the last dose of study drug, to practice the protocol specified contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least  days after the last dose of study drug.
Male participants must agree to use a contraception as detailed in protocol during the treatment period and for at least  days after the last dose of trial treatment and refrain from donating sperm during this period.
Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until  days after the last dose of study drug
Male subjects who are not employing an effective method of birth control from starting dose of study medications (cycle  day ), including dosing interruptions through  months after receipt of study treatment; male subjects should agree to refrain from sperm donation while taking study treatment and for at least  months after the last dose of nab-paclitaxel and at least  days after the last dose of durvalumab; should a female partner of a male patient become pregnant or suspect she is pregnant while participating in the study, he should inform his treating physician and the female partner should call her physician immediately
Are not currently abstinent or do not agree to refrain from sexual activity during the study period and for  months after study drug discontinuation;
Willing to refrain from using other lotions, creams, etc. during the treatment period;
Male participants who are sexually active, must agree, from Study Day  through at least  days after the last dose of study drug, to practice protocol specified methods of contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least  days after the last dose of study drug.
Male subjects must be willing to refrain from sperm donation during the entire study and for  half-lives of study drug plus  days (duration of sperm turnover) after dosing has been completed
Male patients should be willing to use barrier contraception; male patients should be asked to use barrier contraceptives (i.e., by use of condoms) during sex with all of their female partners during the trial and for a washout period of  months; patients should refrain from donating sperm from the start of dosing until  months after discontinuing osimertinib treatment; if male patients wish to father children they should be advised to arrange for freezing of sperm samples prior to the start of osimertinib treatment
Subjects must be willing to refrain from blood donations during study drug therapy and for  weeks after therapy
Male patients should be asked to avoid unprotected sex with all sexual partners but use condoms plus spermicide during the study, and for a washout period of  days after the last dose of study drug; where a sexual partner of a male participant is a woman of child-bearing potential, patients should avoid procreation for  days after completion of study drug treatment; patients should refrain from donating sperm from the start of dosing until  days after discontinuing study treatment; if male patients wish to father children they should be advised to arrange for freezing of sperm samples prior to the start of study treatment
Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for  days following the last dose of study drug
 Males who are unwilling to abstain from sperm donation while on study through  days after receiving the last dose of study drug.
Male subjects must agree to refrain from sperm donation throughout the duration of the study and for  days following the last dose of study drug;
Male participants must agree to use contraception during the treatment period and for ? days, after the last dose of study treatment and refrain from donating sperm during this period. Male participants with pregnant partners must agree to use a condom
For male subjects having intercourse with females of childbearing potential, willingness to abstain from heterosexual intercourse or use  protocol-recommended methods of contraception from the start of pembrolizumab throughout the study treatment period and for  days following the last dose of pembrolizumab; also, male subjects should refrain from sperm donation from the start of pembrolizumab throughout the study treatment period and for  months following the last dose of study drugs
Male participants must be willing to refrain from sperm donation during the entire study and for  half-lives of study drug plus  days (duration of sperm turnover)
Use of highly effective contraception (as defined by protocol) and until  months after the last dose of atezolizumab and for  months after the last dose of alectinib or for  weeks after the last dose of erlotinib, whichever is longer; Males must also refrain from sperm donatation during this same time period. Participants must not be pregnant or breastfeeding.
Men should be willing to use barrier contraception (ie, condoms) and refrain from sperm donation during and after the conduct of the trial.
Refrain from egg cell and blood donation for  days after the final dose of durvalumab.
Refrain from sperm and blood donation for at least  days after the final dose of durvalumab . For Cohort A subject must be transplant non-eligible (TNE) and meet at least one of the following high risk factors:
Male subjects must refrain from donating sperm starting at the planned first dose of investigational product (IP) until  days following the last dose of IP
Sexually active patients, unless surgically sterile, must agree to use condoms as an effective barrier method and refrain from sperm donation during the study treatment and for  months after the end of the study treatment.
refrain from breastfeeding and donating blood or oocytes
refrain from donating blood or sperm
All patients who disagree to refrain from donating blood while on study treatment and for  weeks after discontinuation from this study treatment.
Subjects unwilling to use acceptable methods of contraception. -Female subjects should refrain from breastfeeding throughout this period.
are currently abstinent, and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for  days after study drug discontinuation,
Women must agree to abstain from donating blood during study participation and for at least  days after discontinuation from protocol treatment
Males must agree to abstain from donating blood, semen, or sperm during study participation and for at least  days after discontinuation from protocol treatment
If male, patient must be sterile or willing to use an approved method of contraception from the time of Informed Consent to  days after study drug treatment. Males must be willing to refrain from sperm donation within  days after study treatment.
Subjects unwilling to use acceptable methods of contraception. -Female subjects should refrain from breastfeeding throughout this period.
Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until  days after the last dose of study drug.
FOCBP must have a negative pregnancy test within  days prior to registration on study\r\n* Note: female patients who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for  days following the last dose of study drug
Male participants must agree to use contraception during the treatment period and for ? days, after the last dose of study treatment and refrain from donating sperm during this period. Male participants with pregnant partners must agree to use a condom
Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for  days following the last dose of study drug
Agree to abstain from donating blood while taking study drug therapy and following discontinuation of study drug therapy.  Agree not to share study medication with another person.
Participants who are willing to refrain from donating blood for at least  days after their final dose of MLN and (for male participants) willing to refrain from donating semen for at least  months after their final dose of MLN.
Patients who are willing to refrain from donating blood for at least  days after their final dose of MLN and (for male patients) willing to refrain from donating semen for at least  months after their final dose of MLN
Males must also agree to refrain from donating semen or sperm while on pomalidomide and for  days after discontinuation from this study
Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for  days following the last dose of study drug
Pregnant or lactating female; female subjects who are lactating are eligible if they discontinue nursing prior to the first dose of study drug and refrain from nursing throughout the treatment period and for  days following the last dose of study drug
Refrain from donating blood or semen as defined by protocol
Agree to abstain from donating blood while taking study drug therapy and following discontinuation of study drug therapy.
Are currently abstinent, and do not agree to use a double-barrier method (as described above) or refrain from being sexually active during the study period or for  days after study drug discontinuation
Unwilling to refrain from donation of bodily fluid (blood, platelets, etc.) within  months of last vismodegib dose
Not willing or are unable to refrain from use of any non-study ASA, NSAIDs and leukotriene antagonists during the study period
Refrain from semen or sperm donation while taking IP and for at least  days after the last dose of IP.
Not willing or are unable to refrain from use of any non-study ASA or NSAIDs during the study period
Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for  days following the last dose of study drug
Male subject who is considering fathering a child or donating sperm during the study or for approximately  days after the last dose of study drugs
Male participants are required to use a condom during the entire study period with RO and up to  days after last administration of RO. Male participants should not donate sperm for  days after the last dose of RO.